Skip to Content

Cancer Control Trials

E1Z11: A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Aims: The purpose of this study is to find out what effects, good an/or bad , that anastrozole has on patients and whether the genes and blood can help explain how the study drug, anastrozole affects the body. Specifically, many women who take anastrozole or one of the other aromatase inhibitors (letrozole or exemestane) during treatment for breast cancer report muscle and joint aches, however, the reason that lead to these symptoms are not known. These symptoms have been designated aromatase inhibitor-associated musculoskeletal symptom.
Diagnosis: Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH13-444
Sponsor: ECOG
Contact: Interested patients should contact research coordinator Nancy Haefling at 847.657.5957
Open to Enrollment: Yes